Yangli Pharmaceutical has completed a substantial round of B financing, exclusively backed by Qiming Venture Partners, to advance its clinical programs in innovative drug development.
Target Information
Hangzhou Yangli Pharmaceutical Technology Co., Ltd., founded in 2021 and based in Hangzhou, China, specializes in the research and development of innovative drugs, particularly those classified as Class 1 national innovative drugs. The company focuses on oncology and chronic disease therapies, striving to develop first-in-class and best-in-class drugs with global intellectual property rights. Several of its products are currently in Phase I and Phase II clinical trials.
Yangli Pharmaceutical is committed to addressing unmet clinical needs through differentiated products, adhering to a research and development philosophy of "In China, For Global." Recently, the company completed a substantial round of B financing, which will be utilized to advance its clinical programs.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The pharmaceutical industry in China is rapidly evolving, driven by increasing demand for innovative therapies due to the growing prevalence of chronic diseases and an aging populati
Similar Deals
启明创投
invested in
浙江扬厉医药技术有限公司
in 2025
in a Series B deal
Disclosed details
Transaction Size: $300M